Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10-Year Fabry Outcome Survey (FOS) Analysis
Uma Ramaswami, Michael Beck, Derralynn Hughes, Christoph Kampmann, Jaco Botha, Guillem Pintos-Morell, Michael L West, Dau-Ming Niu, Kathy Nicholls, Roberto Giugliani
Drug Design, Development and Therapy | DOVE MEDICAL PRESS LTD | Published : 2019
The Fabry Outcome Survey is sponsored by Shire Human Genetic Therapies, Inc., a member of the Takeda group of companies. Shire International GmbH, a member of the Takeda group of companies, provided funding to Excel Medical Affairs for support in writing and editing this manuscript and participated in data collection and analysis.